Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies

Authors

  • M. Ferwana,

    Corresponding author
    1. Family Medicine and Primary Care Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia
    • National and Gulf Center for Evidence Based Health Practice, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
    Search for more papers by this author
  • B. Firwana,

    1. National and Gulf Center for Evidence Based Health Practice, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
    2. Department of Internal Medicine, University of Missouri, Columbia, MO
    3. Knowledge and Evaluation Research Unit, Mayo Clinic, Rochester, MN, USA
    Search for more papers by this author
  • R. Hasan,

    1. National and Gulf Center for Evidence Based Health Practice, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
    2. Department of Internal Medicine, University of Missouri, Columbia, MO
    3. Knowledge and Evaluation Research Unit, Mayo Clinic, Rochester, MN, USA
    Search for more papers by this author
  • M. H. Al-Mallah,

    1. National and Gulf Center for Evidence Based Health Practice, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
    2. King Abdul-Aziz Cardiac Center, Riyadh, Saudi Arabia
    Search for more papers by this author
  • S. Kim,

    1. Knowledge and Evaluation Research Unit, Mayo Clinic, Rochester, MN, USA
    2. Department of Urology, Mayo Clinic, Rochester, MN, USA
    Search for more papers by this author
  • V. M. Montori,

    1. Knowledge and Evaluation Research Unit, Mayo Clinic, Rochester, MN, USA
    2. Division of Diabetes and Endocrinology, Mayo Clinic, Rochester, MN, USA
    Search for more papers by this author
  • M. H. Murad

    1. Knowledge and Evaluation Research Unit, Mayo Clinic, Rochester, MN, USA
    2. Division of Preventive Medicine, Mayo Clinic, Rochester, MN, USA
    Search for more papers by this author

Correspondence to: Mazen Ferwana. E-mail: ferwanam@ngha.med.sa

Abstract

Aims

Pioglitazone, a thiazolidinedione, was approved for treatment of Type 2 diabetes. However, several observational studies suggest an association of pioglitazone with an increased risk of bladder cancer in patients with diabetes. Therefore, we sought to perform a systematic review and meta-analysis to evaluate the magnitude of this association and the quality of the supporting evidence.

Methods

Electronic databases were queried to identify controlled studies of pioglitazone that measured the risk of bladder cancer.

Results

Six studies involving 215 142 patients using pioglitazone were included, with a median period of follow-up of 44 months. The hazard of developing bladder cancer was significantly higher in patients using pioglitazone (hazard ratio 1.23; 95% CI 1.09–1.39; I2 = 0%) compared with control groups. The risk of bias was moderate across the six studies. Considering an incidence rate of 20.8 per 100 000 person years, the number needed to harm was five additional cases of bladder cancer per 100 000 person years.

Conclusions

Patients treated with pioglitazone have a slight increased risk of bladder cancer compared to general population. Patient involvement and weighing treatment benefits versus risks should be discussed with patient toward shared decision. Patients with type 2 diabetes with risk factors, such as family history, smoking, or exposure to certain forms of chemotherapy may need to consider other anti-hyperglycemic agents. Also, pioglitazone should be discontinued in type 2 diabetes patients with newly diagnosed bladder cancer.

Ancillary